Literature DB >> 1372003

Thrombomodulin is preferentially expressed in Balb/c lung microvessels.

V A Ford1, C Stringer, S J Kennel.   

Abstract

Previously, two rat monoclonal antibodies where developed which bind distinct epitopes on a murine glycoprotein, P112, which is expressed primarily in lung capillary endothelium. In this paper we show that P112 is identical to the endothelial anticoagulant protein, thrombomodulin (TM). Several lines of evidence support this conclusion. First, amino acid analysis of P112 shows a high degree of homology to TM, and both molecules exhibit the same mobility in gel electrophoresis. Second, P112 and TM share reactivity for two different monoclonal antibodies. Third, purified P112, like TM, acts as a cofactor for protein C activation. Finally, two cDNA clones identified with P112 polyclonal antiserum contain sequence identity with the known TM cDNA sequence. Quantitative analysis of TM (P112) expression using a two-site monoclonal antibody assay demonstrates that significantly higher levels of TM are found in lung in comparison with other highly vascularized organs, i.e. the kidney and liver. Quantitative Northern blot data coincides with the two-site assay data and demonstrates that the high level of TM expression in lung is not due to preferential binding of the monoclonal antibodies to lung TM but rather to increased production of TM mRNA in the lung relative to other highly vascularized organs. It is suggested that expression of TM is highest in cells from continuous endothelium.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372003

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium.

Authors:  Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Arnaud Scherpereel; Eric Simone; Evguenia Arguiri; Samira Tliba; Jeremy Pick; Stephen Kennel; Steven M Albelda; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2007-01-08       Impact factor: 9.776

3.  Does the oxidation of methionine in thrombomodulin contribute to the hypercoaguable state of smokers and diabetics?

Authors:  Wesley E Stites; Jeffrey W Froude
Journal:  Med Hypotheses       Date:  2006-10-24       Impact factor: 1.538

4.  A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.

Authors:  H Weiler-Guettler; P D Christie; D L Beeler; A M Healy; W W Hancock; H Rayburn; J M Edelberg; R D Rosenberg
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

5.  Thrombomodulin is essential for maintaining quiescence in vascular endothelial cells.

Authors:  Hemant Giri; Sumith R Panicker; Xiaofeng Cai; Indranil Biswas; Hartmut Weiler; Alireza R Rezaie
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

6.  A murine model of myocardial microvascular thrombosis.

Authors:  P D Christie; J M Edelberg; M H Picard; A S Foulkes; W Mamuya; H Weiler-Guettler; R H Rubin; P Gilbert; R D Rosenberg
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

7.  Thrombomodulin distribution during murine development.

Authors:  Virginia A Ford; John E Wilkinson; Stephen J Kennel
Journal:  Rouxs Arch Dev Biol       Date:  1993-08

8.  Immunotargeting of liposomes containing lipophilic antitumor prodrugs.

Authors:  A Mori; S J Kennel; L Huang
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

Review 9.  Human microvessel endothelial cells: isolation, culture and characterization.

Authors:  P W Hewett; J C Murray
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

10.  Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.

Authors:  A Mori; S J Kennel; M van Borssum Waalkes; G L Scherphof; L Huang
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.